BioXcel Therapeutics Announces FDA Acceptance for Filing of NDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders I and II

Brenda Snow
Authentic Patient Voice

Matt Turner
Patient Affordability

David Linetsky
Point-of-Care Marketing

Suma Ramadas, PhD
Medical Affairs

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

Joey Cohen
Medication Adherence

Pat Purcell
Meeting Engagement

Stacey Gandler
Brand Nourishment

Matthew Durham
Omnidynamic Marketing

Bud Bilanich
Success Coach

Daniel Sontupe
Market Access

Paul Theisen
Patient Acquisition

Liz Kane
Impactful Strategy